uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome
Show others and affiliations
2007 (English)In: Gynecological Endocrinology, ISSN 0951-3590, E-ISSN 1473-0766, Vol. 23, no 5, 257-266 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Neurosteroids such as allopregnanolone and pregnanolone are suggested to be of importance for the pathophysiology of premenstrual dysphoric disorder. The aim of this study was to investigate whether the luteal-phase serum concentrations of these neurosteroids are associated with improvement of premenstrual symptoms in 12 women with severe premenstrual syndrome after treatment with low-dose gonadotropin-releasing hormone agonist and placebo. METHODS: Daily ratings for mood and physical symptoms were made prior to treatment and throughout the study. Serum progesterone, allopregnanolone and pregnanolone were assessed in the luteal phase (cycle day -9 to cycle day -1). Based on their symptom ratings, subjects were grouped as either buserelin responders (n = 6) or placebo responders (n = 6). RESULTS: Buserelin responders displayed decreased levels of allopregnanolone (p < 0.05) and progesterone (p < 0.05) in parallel with improvement of symptoms. During the placebo treatment, the placebo responders had lower serum allopregnanolone concentrations than buserelin responders (p < 0.05). This was associated with improvement in symptoms compared with pre-treatment ratings. CONCLUSION: Treatment response, whether induced by buserelin or placebo, appears to be associated with a decrease in allopregnanolone concentration.

Place, publisher, year, edition, pages
2007. Vol. 23, no 5, 257-266 p.
Keyword [en]
Adult, Buserelin/administration & dosage/*therapeutic use, Cross-Over Studies, Double-Blind Method, Female, Fertility Agents; Female/administration & dosage/*therapeutic use, Humans, Luteal Phase/blood, Placebo Effect, Pregnanolone/*blood, Premenstrual Syndrome/blood/*drug therapy, Progesterone/*blood, Treatment Outcome
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-15036DOI: 10.1080/09513590701253511ISI: 000247686800004PubMedID: 17558683OAI: oai:DiVA.org:uu-15036DiVA: diva2:42807
Available from: 2008-02-04 Created: 2008-02-04 Last updated: 2011-02-09Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=17558683&dopt=Citation

Search in DiVA

By author/editor
Poromaa, Inger Sundström
By organisation
Department of Women's and Children's Health
In the same journal
Gynecological Endocrinology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 162 hits
ReferencesLink to record
Permanent link

Direct link